Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425405 | 0.82 | ALDH1A1 (0.55) | ALDH1A1GAACA1CA2MAPT | |
| SCHEMBL1136944 | 0.82 | CA12 (0.48) | ALDH1A1GAACA1ACHEBACE1 | |
| SCHEMBL31606978 | 0.82 | CA12 (0.48) | ALDH1A1GAACA1ACHEBACE1 | |
| SCHEMBL5100819 | 0.79 | ALDH1A1 (0.51) | ALDH1A1GAACA1CA2MAPT | |
| SCHEMBL31300043 | 0.79 | CYP1A2 (0.58) | ALDH1A1GAAMAPKAPK2MAPTKMT2A | |
| SCHEMBL4401844 | 0.78 | KMT2A (0.56) | ALDH1A1GAAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL5097622 | 0.78 | ALDH1A1 (0.50) | ALDH1A1GAACA1CA2MAPT | |
| SCHEMBL31300041 | 0.78 | ALDH1A1 (0.59) | ALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL6680791 | 0.77 | NQO2 (0.44) | ALDH1A1GAACA1CA2MAPT | |
| SCHEMBL27761091 | 0.76 | SMN1; SMN2 (0.58) | ALDH1A1GAAKDM4CMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263550-A1 | THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-8012971-B2 | Therapeutic agent for chronic obstructive pulmonary disease | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090131439-A1 | Therapeutic agent for chronic obstructive pulmonary disease | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1875915-A1 | THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131439-A1 | Therapeutic agent for chronic obstructive pulmonary disease | CFTR, SCLY, ELANE | ALDH1A1 2234/4885GAA 2258/4885KDM4C 3621/4885 |
| US-20110263550-A1 | THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | CFTR, SCLY, ELANE | ALDH1A1 2234/4885GAA 2258/4885KDM4C 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.